Functional improvement of dystrophic muscle by myostatin blockade
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Mice and cattle with mutations in the myostatin (GDF8) gene show a marked increase in body weight and muscle mass, indicating that this new member of the TGF-beta superfamily is a negative regulator of skeletal muscle growth. Inhibition of the myostatin gene product is predicted to increase muscle mass and improve the disease phenotype in a variety of primary and secondary myopathies. We tested the ability of inhibition of myostatin in vivo to ameliorate the dystrophic phenotype in the mdx mouse model of Duchenne muscular dystrophy (DMD). Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies for three months resulted in an increase in body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse muscle along with a significant decrease in muscle degeneration and concentrations of serum creatine kinase. The functional improvement of dystrophic muscle by myostatin blockade provides a novel, pharmacological strategy for treatment of diseases associated with muscle wasting such as DMD, and circumvents the major problems associated with conventional gene therapy in these disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interest in myostatin was generated by recent studies where antibodies for myostatin were created and administered to adult rodents, which resulted in an increase in body mass, muscle mass, muscle size, and strength [11,12].”
From Effects of methoxyisoflavone, ecdysterone, and sulfo-polysaccharide supplementation on training adaptations in resistance-trained males (2006) · cites this paper as [12]
Citations
Cites
Textbook of Medical Physiology
(1966) · Annals of Internal Medicine · doi:10.7326/0003-4819-64-6-1363_2 · Cited by 9,749
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
TEXTBOOK OF MEDICAL PHYSIOLOGY
GUYTON, A. C. (1967) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196701000-00031 · Cited by 2,837
Dystrophin expression in the mdx mouse restored by stem cell transplantation
Gussoni, E., Soneoka, Y., Strickland, C. D., Buzney, E. A., Khan, M. K., Flint, A. F., Kunkel, L. M., & Mulligan, R. C. (1999) · Nature · doi:10.1038/43919 · Cited by 1,802 · cited 1×
“In comparison with conventional transgenic, cell and gene therapy approache”
BackgroundX chromosome-linked muscular dystrophy (mdx) in the mouse
Bulfield, G., Siller, W. G., Wight, P. A., & Moore, K. J. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.4.1189 · Cited by 1,765
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616 · cited 1×
“Alterations in Smad 2 and 3 phosphorylation would be predicted to regulate the formation of Smad complexes, their nuclear translocation and transcriptional regulation of genes associated with commitment of muscle progenitor”
BackgroundA deletion in the bovine myostatin gene causes the double–muscled phenotype in cattle
Grobet, L., Royo Martin, L. J., Poncelet, D., Pirottin, D., Brouwers, B., Riquet, J., Schoeberlein, A., Dunner, S., Ménissier, F., Massabanda, J., et al. (1997) · Nature Genetics · doi:10.1038/ng0997-71 · Cited by 1,556
Dystrophin protects the sarcolemma from stresses developed during muscle contraction
Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., & Sweeney, H. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3710 · Cited by 1,526 · cited 1×
“The regimen did not completely reverse dystrophic changes; physiological parameters evaluated by ex vivo tests, such as susceptibility to damage by lengthening contraction”
BackgroundAhima, R. S., & Flier, J. S. (2000) · Annual Review of Physiology · doi:10.1146/annurev.physiol.62.1.413 · Cited by 1,428
Self-citation
Research works printed but not linked: 2
- Jalenak, M. et al. Transcriptional changes arising from in vivo inhibition of myostatin. J. Neurol. Sci. 199 (suppl)., S83 (2002)
- Engel, A. G. & Franzini-Armstrong, C. Myology (McGraw-Hill, New York, 1994)
Cited by
Items 501–600 of 853
Sakuma, K., Nakao, R., Inashima, S., Hirata, M., Kubo, T., & Yasuhara, M. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0884-5 · Cited by 21
“Interestingly, subcutaneous injection of a myostatin inhibitor prevented muscle atrophy in mdx mice [ 1 ].”
BackgroundInfluentialEffect of N‐Terminal Acylation on the Activity of Myostatin Inhibitory Peptides
Takayama, K., Nakamura, A., Rentier, C., Mino, Y., Asari, T., Saga, Y., Taguchi, A., Yakushiji, F., & Hayashi, Y. (2016) · ChemMedChem · doi:10.1002/cmdc.201500533 · Cited by 21
Kim, M.-J., & O’Connor, M. B. (2020) · Development · doi:10.1242/dev.190868 · Cited by 30
Bushby, K. M. D., & Griggs, R. C. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.01.006 · Cited by 24
“It has been an exciting time for DMD research, with several possible treatment modalities for DMD entering early human trials or showing promise in animal experiments (see Table 2) [7–24].”
BackgroundChoi, D. H., Yang, J., & Kim, Y. (2019) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2018.12.009 · Cited by 24
嵩原, 由., Tsuchida, K., Nakatani, M., Murakami, T., Kurisaki, A., Hashimoto, O., Ohuchi, H., Kurose, H., Mori, K. J., Kagami, S., et al. (2007) · The Journal of Medical Investigation · doi:10.2152/jmi.54.276 · Cited by 24
Asari, T., Takayama, K., Nakamura, A., Shimada, T., Taguchi, A., & Hayashi, Y. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00420 · Cited by 20
Geng, J., Liu, G., Peng, F., Yang, L., Cao, J., Li, Q., Chen, F., Kong, J., Pang, R., & Zhang, C. (2012) · Cytotherapy · doi:10.3109/14653249.2012.688944 · Cited by 20
Identification of decorin derived peptides with a zinc dependent anti-myostatin activity
Guiraud, S., van Wittenberghe, L., Georger, C., Scherman, D., & Kichler, A. (2012) · Neuromuscular Disorders · doi:10.1016/j.nmd.2012.07.002 · Cited by 20
“A single gly Considering the therapeutic potential of inhibition of myostatin in muscle-degenerative and wasting conditions, such as muscular dystrophies [19] and cachexia induced by cancer [20], we investigated the potential of decorin and fragments thereof to inactivate myostatin in vitro and in vivo.”
Zammit, P. S., & Partridge, T. A. (2002) · Nature Medicine · doi:10.1038/nm1202-1355 · Cited by 20
“In the November 29 issue of Nature , Bogdanovich et al”
BackgroundLu‐Nguyen, N., Ferry, A., Schnell, F. J., Hanson, G. J., Popplewell, L. J., Dickson, G., & Malerba, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz125 · Cited by 19
The University of North Carolina at Chapel Hill University Libraries (2014) · Europe PMC (PubMed Central) · doi:10.17615/v6v7-mw24 · Cited by 20
Ishizaki, M., Maeda, Y., Kawano, R., Suga, T., Uchida, Y., Uchino, K., Yamashita, S., Kimura, E., & Uchino, M. (2011) · Molecular Therapy · doi:10.1038/mt.2011.58 · Cited by 20
Attenuation of Conducted Vasodilation in Skeletal Muscle Arterioles during Hyperhomocysteinemia
Givvimani, S., Narayanan, N., Armaghan, F., Pushpakumar, S. B., & Tyagi, S. C. (2013) · Pharmacology · doi:10.1159/000350394 · Cited by 19
Amali, A. A., Lin, C. J., Chen, Y., Wang, W.-L., Gong, H., Rekha, R. D., Lu, J., Chen, T. T., & Wu, J. (2008) · Journal of Biomedical Science · doi:10.1007/s11373-008-9250-2 · Cited by 20
“Blockade of endogenous Mstn by using intraperitoneal injections of antiMSTN antibodies, for three months resulted in an increased body weight, muscle mass, muscle size and absolute muscle strength in mdx mouse along with a significant decrease in muscle degeneration and concentration of creatine kinase [27].”
BackgroundQiao, C., Li, J., Zheng, H., Bogan, J. R., Li, J., Yuan, Z., Zhang, C., Bogan, D., Kornegay, J. N., & Xiao, X. (2008) · Human Gene Therapy · doi:10.1089/hgt.2008.135 · Cited by 20
Minderis, P., Kilikevičius, A., Baltušnikas, J., Alhindi, Y. Z., Venckūnas, T., Bünger, L., Lionikas, A., & Ratkevičius, A. (2015) · Scandinavian Journal of Medicine and Science in Sports · doi:10.1111/sms.12532 · Cited by 18
“antibodies induce an increase in muscle mass of dystrophic mouse model (Bogdanovich et al., 2002).”
Masanés, F., López, M. N., Sacanella, E., & Soto, A. L. (2010) · Seminarios de la Fundación Española de Reumatología · doi:10.1016/j.semreu.2009.10.003 · Cited by 50
Kawakami, E., Kinouchi, N., Adachi, T., Ohsawa, Y., Ishimaru, N., Ohuchi, H., Sunada, Y., Hayashi, Y., Tanaka, E. I., & Noji, S. (2011) · Development Growth & Differentiation · doi:10.1111/j.1440-169x.2010.01221.x · Cited by 18
“In a previous study, inhibition of myostatin using anti-myostatin blocking antibodies was employed in an effort to increase muscle mass (Bogdanovich et al. 2002).”
BackgroundMethodResultInfluentialMyostatin and NF-κB Regulate Skeletal Myogenesis Through Distinct Signaling Pathways
Bakkar, N., Wackerhage, H., & Guttridge, D. C. (2005) · Signal Transduction · doi:10.1002/sita.200400039 · Cited by 23
Role of transcription factors in skeletal muscle and the potential for pharmacological manipulation
Martin, P. T. (2003) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(03)00050-x · Cited by 18
Hurley-Novatny, A. C., Chang, D., Murakami, K., Wang, L., & Li, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1398050 · Cited by 21
Aversa, Z., Alamdari, N., & Hasselgren, P.-O. (2011) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2011.591365 · Cited by 18
Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases
Chiu, W., Hsun, Y.-H., Chang, K.-J., Yarmishyn, A. A., Hsiao, Y., Chien, Y., Chien, C., Ma, C., Yang, Y.-P., Tsai, P., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249589 · Cited by 18
Skrzypczak, D., Skrzypczak-Zielińska, M., Ratajczak, A. E., Szymczak‐Tomczak, A., Eder, P., Słomski, R., Dobrowolska, A., & Krela‐Kaźmierczak, I. (2021) · Biomedicines · doi:10.3390/biomedicines9101301 · Cited by 21
Cachexia in chronic heart failure: endocrine determinants and treatment perspectives
Mangner, N., Matsuo, Y., Schuler, G. C., & Adams, V. (2012) · Endocrine · doi:10.1007/s12020-012-9767-z · Cited by 18
Yuan, X., Bhat, O. M., Lohner, H., Li, N., Zhang, Y., & Li, P. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00342.2018 · Cited by 17
“We also examined the effect of GDF11 gene induction or activation on CASMC phenotypic transition by overexpression of the GDF11 gene using GDF11-specific CRISPR-cas9 activating plasmids or treated cells with a known GDF11 inducer, TSA (5, 11, 14, 48, 53).”
BackgroundMethodChain-Shortened Myostatin Inhibitory Peptides Improve Grip Strength in Mice
Takayama, K., Asari, T., Saitoh, M., Nirasawa, K., Sasaki, E., Roppongi, Y., Nakamura, A., Saga, Y., Shimada, T., Ikeyama, H., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00174 · Cited by 17
Loss of cIAP1 attenuates soleus muscle pathology and improves diaphragm function in mdx mice
Enwere, E. K., Boudreault, L., Holbrook, J., Timusk, K., Earl, N., LaCasse, E. C., Renaud, J., & Korneluk, R. G. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds493 · Cited by 18
Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy
Yue, Y., Binalsheikh, I. M., Leach, S. B., Domeier, T. L., & Duan, D. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1124039 · Cited by 16
Efficient and Specific Generation of MSTN-Edited Hu Sheep Using C-CRISPR
Guo, R., Wang, H., Meng, C., Gui, H., Li, Y., Chen, F., Zhang, C., Zhang, H., Ding, Q., Zhang, J., et al. (2023) · Genes · doi:10.3390/genes14061216 · Cited by 19
“Natural mutations that either inactivate the encoded protein or suppress its quantity cause enhanced muscling in humans [6], sheep [7–9], cattle [10–12], pigs [13], and dogs [14].”
BackgroundExercise alters myostatin protein expression in sedentary and exercised streptozotocin-diabetic rats
Dibai, D. B., Bueno, P., Nonaka, K. O., Selistre-de-Araújo, H. S., & Leal, A. M. O. (2015) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000028 · Cited by 16
“In addition, there is evidence suggesting that exercise increases insulin secretion and has a protective effect in STZ-induced diabetes by decreasing oxidative stress and preserving pancreatic beta cell integrity (21-23) observed was increasing muscle mass by myostatin inhibition elevates basal metabolic rate dystroph…”
BackgroundWomack, J. E. (2006) · KARGER eBooks · doi:10.1159/000095095 · Cited by 18
Zhao, B., Li, E. J., Wall, R. J., & Yang, J. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-305 · Cited by 18
“Increased levels of myostatin have been implicated in AIDS patients, sarcopenia, chronic human muscle disuse atropy, glucocorticoid-induced muscle atrophy [37-42] A systemic administration of myostatin also induced cachexia [43] while functional blockage of myosatin by intraperitoneal injection of its antibody increas…”
BackgroundGuertler, P., Brandl, C., MEYER, H. H. D., & Tichopád, A. (2012) · Journal of Consumer Protection and Food Safety · doi:10.1007/s00003-012-0778-8 · Cited by 18
“Muscle growth and cell cycle are regulated by cyclin-dependent kinase (CDK2), cyclin A and cyclin D1 (Lee and McPherron 1999), whereas myostatin acts as an antagonist of this regulation (Bogdanovich et al. 2002).”
Han, D., Huang, C.-H., Chen, S., & Yang, W. (2017) · Journal of the International Society of Sports Nutrition · doi:10.1186/s12970-016-0160-9 · Cited by 16
“Myostatininhibiting antibody and muscle-specific expression of IGF-I were shown to increase the muscle mass and function of mdx mice, an animal model of Duchenne muscular dystrophy [14, 15].”
BackgroundDing-biao, L., Zhang, K., Chen, D., Xue‐mei, D. I. N. G., & Yu, B. (2009) · Animal Science Journal · doi:10.1111/j.1740-0929.2009.00666.x · Cited by 17
“Immunoneutralization of myostatin as a potential approach to improve skeletal muscle growth has been demonstrated in laboratory animals (Bogdanovich et al. 2002; Whittemore et al. 2003; Kim et al. 2006).”
BackgroundResultYang, Z., Zhang, J., Cong, H., Huang, Z., Sun, L., Liu, C., & Tien, P. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1216 · Cited by 17
“Furthermore, two research groups reported that blocking the action of myostatin could treat Duchenne muscular dystrophy and perhaps other muscle-wasting diseases by increasing muscle mass and thus muscle strength [17,18].”
BackgroundApplications of RNA interference-based gene silencing in animal agriculture
Long, C. R., Tessanne, K. J., & Golding, M. C. (2009) · Reproduction Fertility and Development · doi:10.1071/rd09211 · Cited by 16
Kee, H. J., Kim, J. R., Joung, H., Choe, N., Lee, S., Eom, G. H., Kim, J., Geyer, S. H., Jijiwa, M., Kato, T., et al. (2011) · Cell Death and Differentiation · doi:10.1038/cdd.2011.72 · Cited by 19
Increased expression of decorin during the regeneration stage of mdx mouse
Abe, S., Hirose, D., Kado, S., Iwanuma, O., Saka, H., Yanagisawa, N., & Ide, Y. (2009) · Anatomical Science International · doi:10.1007/s12565-009-0039-9 · Cited by 15
“In fact, antibody-mediated myostatin blockade in mdx mice was found to improve the pathophysiology and muscle regeneration (Bogdanovich et al., 2002).”
BackgroundHEXIM1 controls satellite cell expansion after injury to regulate skeletal muscle regeneration
Peng, H., Chen, K., Huang, B., Liu, M., Cui, M., Rozenberg, I., Chaqour, B., Pan, X., Barton, E. R., Jiang, X.-C., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62818 · Cited by 15
“Blockade of myostatin, a powerful inhibitor of skeletal muscle growth, enhances global myogenesis, including both muscle maintenance and regeneration (51), while haplodeficiency of Hexim1 specifically promotes muscle regeneration after injury.”
Self-citationmiRNA Transcriptome of Hypertrophic Skeletal Muscle with Overexpressed Myostatin Propeptide
Javed, R., Jing, L., Yang, J., Li, X., Cao, J., & Zhao, S. (2014) · BioMed Research International · doi:10.1155/2014/328935 · Cited by 15
“miRNA Transcriptome of Hypertrophic Skeletal Muscle with”
Insulin-like growth factor-I is required to maintain muscle volume in adult mice
Nakamura, S., Sato, Y., Kobayashi, T., Oike, T., Kaneko, Y., Miyamoto, K., Funayama, A., Oya, A., Nishiwaki, T., Matsumoto, M., et al. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0964-6 · Cited by 15
Easwvaran, S., Bhassu, S., Maningas, M. B. B., & Othman, R. Y. (2019) · Journal of the World Aquaculture Society · doi:10.1111/jwas.12607 · Cited by 16
Discovery of a follistatin-derived myostatin inhibitory peptide
Saitoh, M., Takayama, K., Hitachi, K., Taguchi, A., Taniguchi, A., Tsuchida, K., & Hayashi, Y. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126892 · Cited by 15
Fakhfakh, R., Lee, S.-J., & Tremblay, J. P. (2012) · Cell Transplantation · doi:10.3727/096368911x627480 · Cited by 15
The Ins and Outs of Satellite Cell Myogenesis: The Role of the Ruling Growth Factors
Shefer, G., & Yablonka‐Reuveni, Z. (2008) · Springer eBooks · doi:10.1007/978-1-4020-6768-6_6 · Cited by 19
“In the mdx mouse model of Duchenne muscular dystrophy, deletion of the myostatin gene or treatment with a myostatin dominantnegative polypeptide enhanced muscle mass and reduced disease severity (Wagner et al., 2002; Bogdanovich et al., 2002; Bogdanovich et al., 2005).”
The effect of myostatin silencing by lentiviral-mediated RNA interference on goat fetal fibroblasts
Lü, J., Wei, C., Zhang, X., Xu, L., Zhang, S., Liu, J., Cao, J., Zhao, F., Zhang, L., Li, B., et al. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2494-6 · Cited by 16
“Recent studies have suggested that myostatin may also regulate skeletal muscle mass in adults [11, 12].”
Takayama, K., Hitachi, K., Okamoto, H., Saitoh, M., Odagiri, M., Ohfusa, R., Shimada, T., Taguchi, A., Taniguchi, A., Tsuchida, K., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00705 · Cited by 14
High Throughput Screening in Duchenne Muscular Dystrophy: From Drug Discovery to Functional Genomics
Gintjee, T. J., Magh, A., & Bertoni, C. (2014) · Biology · doi:10.3390/biology3040752 · Cited by 15
“Alternative strategies to DMD have focused on upregulating the expression of proteins like utrophin that could compensate for the loss of dystrophin [36–41] or have aimed at ameliorating the pathology by increasing muscle strength [42–44], reducing muscle fibrosis [45–47], and decreasing inflammation [48–53].”
BackgroundMcLoon, L. K. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00176.2008 · Cited by 14
“unusual. Myostatin-null/mdx mice, for example, showed improved skeletal muscle function ( 4 ),”
BackgroundWhen Less Means More: Impact of Myostatin in Animal Breeding
Georges, M. (2010) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152210793663793 · Cited by 16
Zakria, H. M., Han, B., Yue, F., Mu, L., Fang, Y., Li, X., Xu, K., & Zhang, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109147 · Cited by 14
Kramerova, I. A., Marinov, M., Owens, J. M., Lee, S., Becerra, D., & Spencer, M. J. (2020) · The Journal of Physiology · doi:10.1113/jp279943 · Cited by 15
“In the mdx model of DMD, myostatin inhibition improved muscle mass and function (Bogdanovich et al. 2002; Nakatani et al. 2008; Qiao et al. 2008; Murphy et al. 2010); however, in a mouse model of LGMD R2 (dysferlin-deficient) myostatin inhibition exacerbated the dystrophic phenotype, despite an…”
BackgroundInfluentialIncreased Myostatin Synthesis in Rat Gastrocnemius Muscles under High-Protein Diet
Nakazato, K., Hirose, T., & Song, H. (2006) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.16.2.153 · Cited by 15
Effect of maternal myostatin antibody on offspring growth performance and body composition in mice
Liang, Y., Yeh, J., & Ou, B. (2007) · Journal of Experimental Biology · doi:10.1242/jeb.02665 · Cited by 18
“THE JOURNAL OF EXPERIMENTAL BIOLOGY 481Maternal myostatin Ab on offspring growth growth performance in animals is due to the hyperplasia and hypertrophy in skeletal muscle (Bogdanovich et al., 2002).”
BackgroundADAM12 overexpression does not improve outcome in mice with laminin α2-deficient muscular dystrophy
Guo, L. T., Shelton, G. D., Wewer, U. M., & Engvall, E. (2005) · Neuromuscular Disorders · doi:10.1016/j.nmd.2005.06.019 · Cited by 14
Kurokawa, M., Sato, F., Aramaki, S., Soh, T., Yamauchi, N., & Hattori, M. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-009-0158-6 · Cited by 15
Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy
Moore, U., Fernández‐Simón, E., Schiava, M., Cox, D., Gordish‐Dressman, H., James, M. K., Mayhew, A. G., Wilson, I., Guglieri, M., Rufibach, L., et al. (2023) · Neuromuscular Disorders · doi:10.1016/j.nmd.2023.01.001 · Cited by 14
Cell surface and gene expression regulation molecules in dystrophinopathy: mdx vs. Duchenne
Fadić, R. (2005) · Biological Research · doi:10.4067/s0716-97602005000400010 · Cited by 17
“Blockade of endogenous myostatin by using intraperitoneal injections of blocking antibodies resulted in an improvement of the phenotype of the mdx mouse (Bogdanovich et al., 2002); a similar result was obtained with a myostatin-null mdx mouse (Wagner et al., 2002).”
ResultLeung, D. G., Bocchieri, A. E., Ahlawat, S., Jacobs, M. A., Parekh, V. S., Braverman, V., Summerton, K., Mansour, J., Stinson, N., Bibat, G., et al. (2021) · Muscle & Nerve · doi:10.1002/mus.27259 · Cited by 14
Hekmatikar, A. H. A., Nelson, A. R., & Petersen, A. C. (2023) · BMC Cancer · doi:10.1186/s12885-023-11391-3 · Cited by 15
“Myostatin is a negative regulator of skeletal muscle mass, with high levels causing muscle atrophy, while low or no expression causes muscle hypertrophy [32].”
BackgroundWalpurgis, K., Thomas, A., Schänzer, W., & Thevis, M. (2015) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500043 · Cited by 14
FER-1/Dysferlin promotes cholinergic signaling at the neuromuscular junction in C. elegans and mice
Krajacic, P., Pistilli, E. E., Tanis, J. E., Khurana, T. S., & Lamitina, S. T. (2013) · Biology Open · doi:10.1242/bio.20135637 · Cited by 14
“Upon completion of the in vivo experiments, mice were euthanized by placing them in a 100% CO2 chamber for three minutes, followed by cervical dislocation.”
MethodSelf-citationGenetic doping and health damages.
Fallahi, A., Ravasi, A., & Farhud, D. (2011) · Europe PMC (PubMed Central) · Cited by 13
Myostatin: genetic variants, therapy and gene doping
Yamada, A. K., Verlengia, R., & Júnior, C. R. B. (2012) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502012000300003 · Cited by 16
“In vivo injections of MSTN blockade antibody (JA16 neutralizing monoclonal antibody) in MDX mice increase both skeletal muscle hypertrophy and strength, and can be used as a therapeutic strategy (Bogdanovich et al., 2002).”
BackgroundA Quantitative Trait Locus on 13q14.2 for Trunk Strength
Huygens, W., Thomis, M. A., Peeters, M., Aerssens, J., Janssen, R. G. J. H., VLIETINCK, R. F., & Beunen, G. P. (2004) · Twin Research · doi:10.1375/1369052042663850 · Cited by 13
Myostatin's marvels: From muscle regulator to diverse implications in health and disease
Sharma, S., & Patil, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4106 · Cited by 13
“8 – 15 2 | MECHANISMS OF MYOSTATIN ACTION: FROM SIGNALLING PATHWAYS TO FUNCTIONAL OUTCOMES”
Bromer, F. D., Lodberg, A., Eijken, M., Andersen, C. B. F., Poulsen, M. F., Thomsen, J. S., & Brüel, A. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13718 · Cited by 13
Serum Myostatin and Follistatin Levels in Patients With Dermatomyositis and Polymyositis
de Sordi, C. M., dos Reis-Neto, E. T., Keppeke, G. D., Shinjo, S. K., & Sato, E. I. (2021) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001806 · Cited by 12
“In dystrophies such as Duchenne muscular dystrophy, blocking myostatin improved the function and volume of injured muscle tissues.(11,23) There is no consensus in the literature regarding myostatin and follistatin levels in patients with DM and PM.”
BackgroundWide ranges of serum myostatin concentrations in Duchenne muscular dystrophy patients
Awano, H., Takeshima, Y., Okizuka, Y., Saiki, K., Yagi, M., & Matsuo, M. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.01.024 · Cited by 12
Jørgensen, L. H., Sellathurai, J., Davis, E. E., Thedchanamoorthy, T., Al-Bader, R. W. A., Jensen, C. H., & Schrøder, H. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060692 · Cited by 12
“The Myostatin Pathway is Affected by Transgenic Ovine Dlk1 Myostatin, a member of the TGFb superfamily, is a known inhibitor of muscle growth active in late regeneration [22,23].”
BackgroundRespiratory muscle weakness in the Zucker diabetic fatty rat
Allwood, M. A., Foster, A., Arkell, A. M., Beaudoin, M., Snook, L. A., Romanova, N. A., Murrant, C. L., Holloway, G. P., Wright, D. C., & Simpson, J. A. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00447.2014 · Cited by 12
Kvedaras, M., Minderis, P., Krusnauskas, R., Lionikas, A., & Ratkevičius, A. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.110751 · Cited by 13
Challenges for gene therapy for muscular dystrophy
Mendell, J. R., & Clark, K. R. (2006) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-996-0009-8 · Cited by 14
“Therefore, it may be beneficial to block or reduce myostatin to promote regeneration and reduce fibrosis in muscular dystrophy, as has been shown in the mdx mouse model [ 56 ].”
BackgroundPharmacology of manipulating lean body mass
Sepulveda, P. V., Bush, E. D., & Baar, K. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12320 · Cited by 15
Translating Mighty Mice into Neuromuscular Therapeutics
Hoffman, E. P., & Escolar, D. M. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.060270 · Cited by 15
“In the relatively young and clinically mild mdx mouse, myostatin blockade showed significant improvement in size and strength.(13,14) On the other hand, block of myostatin by use of follistatin in the very severe dy/dy mice led to smaller muscles and an earlier death.”
BackgroundElashry, M. I., Schneider, V. C., Heimann, M., Wenisch, S., & Arnhold, S. (2025) · Journal of Developmental Biology · doi:10.3390/jdb13010005 · Cited by 11
“…have documented positive outcomes following either myostatin deletion or the blocking of its activity using various means, including antibodies [44,45], overexpression of the inactive propeptide domain [46–48], zinc finger nucleases in cattle [49] and CRISPR/Cas9 editing in guinea pigs [38].”
Zhong, C., Zeng, X., Yi, X., Yang, Y., Hu, J., Yin, R., & Chen, X. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030158 · Cited by 13
Myostatin dysfunction does not protect from fasting-induced loss of muscle mass in mice.
Fokin, A., Minderis, P., Venckūnas, T., Lionikas, A., Kvedaras, M., & Ratkevičius, A. (2019) · PubMed Central · Cited by 15
Inhibition of Rev-erbα ameliorates muscular dystrophy
Xiong, X., Gao, H., Lin, Y., Yechoor, V. K., & Ma, K. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112766 · Cited by 13
Role and Function of Wnts in the Regulation of Myogenesis: When Wnt Meets Myostatin
Fédon, Y., Bonnieu, A., Gay, S., Vernus, B., Bacou, F., & Bernardi, H. (2012) · InTech eBooks · doi:10.5772/48330 · Cited by 14
“Myostatin acts through the receptor-associated proteins Smad2 and Smad3 [33,212,213].”
BackgroundXing, H. J., Wang, Z. Y., Zhong, B., Ying, S. J., Nie, H., Zhou, Z. R., Fan, Y. X., & Wang, F. (2014) · Genetics and Molecular Research · doi:10.4238/2014.july.24.4 · Cited by 13
Béchir, N., Pecchi, É., Relizani, K., Vilmen, C., Fur, Y. L., Bernard, M., Amthor, H., Bendahan, D., & Giannesini, B. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00370.2015 · Cited by 11
“Disruption of the ActRIIB signaling pathway leads to a rapid and massive increase in muscle mass resulting from fiber hypertrophy with increased myofiber protein synthesis (10, 58).”
BackgroundDrugs of Muscle Wasting and Their Therapeutic Targets
Sakuma, K., & Yamaguchi, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1435-3_21 · Cited by 14
Design and synthesis of potent myostatin inhibitory cyclic peptides
Rentier, C., Takayama, K., Saitoh, M., Nakamura, A., Ikeyama, H., Taguchi, A., Taniguchi, A., & Hayashi, Y. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.02.019 · Cited by 11
Bongiorni, S., Valentini, A., & Chillemi, G. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00014 · Cited by 12
“…of MSTN activity such as the follistatin which hinders access to signaling receptors on skeletal muscle (Sumitomo et al., 1995), are considered as potential therapeutics in the treatment of muscle-wasting disorders such as muscular dystrophy and sarcopenia (Bogdanovich et al., 2002, 2005).”
BackgroundApplying switchable Cas9 variants to in vivo gene editing for therapeutic applications
Mills, E. M., Barlow, V. L., Luk, L. Y. P., & Tsai, Y. (2019) · Cell Biology and Toxicology · doi:10.1007/s10565-019-09488-2 · Cited by 10
Tissue Therapy: Implications of Regenerative Medicine for Skeletal Muscle
Wei, S., & Huard, J. (2008) · Elsevier eBooks · doi:10.1016/b978-012369410-2.50074-7 · Cited by 10
Takemoto, Y., Inaba, S., Zhang, L., Baba, K., Hagihara, K., & Fukada, S. (2017) · Clinical Nutrition Experimental · doi:10.1016/j.yclnex.2017.08.003 · Cited by 10
“The effect of myostatin has been also evaluated using B10-mdx mice [12].”
BackgroundCircadian Clock in Muscle Disease Etiology and Therapeutic Potential for Duchenne Muscular Dystrophy
Kiperman, T., & Ma, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094767 · Cited by 9
“However, despite initial compelling results of myostatin inhibition in pre-clinical models [150,151], these efforts have largely been unsuccessful in clinical trials for DMD patients [152].”
BackgroundErythropoietin reduces the expression of myostatin in mdx dystrophic mice
Feder, D., Rugollini, M., Junior, A. C. S., Oliveira, L., Lioi, V. P. P., dos Santos, R., Guimarães‐Ferreira, L., Nunes, M. T., de Carvalho, M. H. C., Delgado, P. O., et al. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20143858 · Cited by 9
“The injection of anti-myostatin monoclonal antibodies into mdx mice on a weekly basis for a period of 3 months resulted in muscle mass increases up to 35% in individual muscles after myostatin blockade (29).”
BackgroundKim, K. H., Kim, Y. S., & Yang, J. (2011) · Muscle & Nerve · doi:10.1002/mus.21950 · Cited by 11
The quasi-parallel lives of satellite cells and atrophying muscle
Biressi, S., & Gopinath, S. D. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00140 · Cited by 11
“Several members of the TGFβ superfamily, including Myostatin, TGFβ1, and TGFβ2 have been implicated in the progression of different forms of muscular dystrophy (Yamazaki et al., 1994; Bogdanovich et al., 2002; Wagner et al., 2002; Andreetta et al., 2006; Onofre-Oliveira et al., 2012; Biressi et al., 2014).”
BackgroundBaltušnikas, J., Kilikevičius, A., Venckūnas, T., Fokin, A., Bünger, L., Lionikas, A., & Ratkevičius, A. (2015) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2014-0513 · Cited by 10
Are big muscles necessarily good muscles?
Nadeau, A., & Karpati, G. (2008) · Annals of Neurology · doi:10.1002/ana.21395 · Cited by 9
“The method of producing a deficiency of the myostatin effect was one that has been proved to be effective in mice in preclinical experiments.(10) However, there are other potential methods, based on known biochemical/molecular mechanisms(15) (Fig), to obtain a similar or even better effect.”
BackgroundMethodLee, S.-J. (2012) · Muscle · doi:10.1016/b978-0-12-381510-1.00079-x · Cited by 8
Chen, Y.-W., Bittel, A. J., Bittel, D. C., Moon, Y. J., McCormack, N. M., & Jaiswal, J. K. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-88361-3_11 · Cited by 10
Population PK and PD Analysis of Domagrozumab in Pediatric Patients with Duchenne Muscular Dystrophy
Wojciechowski, J., Purohit, V. S., Harnisch, L. O., Dua, P., Tan, B., & Nicholas, T. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2747 · Cited by 9
“In mdx mouse DMD models, loss or inhibition of myostatin leads to increased muscle mass and strength, and decreased fibrosis and fat substitution.(8) Inhibition of myostatin has therefore been investigated as a therapeutic target in musclewasting diseases, such as DMD.”
Background
Metadata
- Authors
- Bogdanovich, S., Krag, T. O. B., Barton, E. R., Morris, L. D., Whittemore, L.-A., Ahima, R. S., & Khurana, T. S.
- Affiliations
- University of Pennsylvania (US)
- Pfizer (United States) (US)
- Corresponding author
- Khurana, Tejvir S.
- Venue
- Nature
- Published
- 2002-11
- Volume
- 420
- Issue
- 6914
- Pages
- 418-421
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2083700023
- Semantic Scholar
- 590fb54cd1f2d89d44f4e1ad999be802dc756277
- Cited by
- 831
- References
- 31
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 19 · 2023: 15 · 2022: 21 · 2021: 20 · 2020: 23 · 2019: 32 · 2018: 23 · 2017: 34 · 2016: 28 · 2015: 43 · 2014: 34 · 2013: 38 · 2012: 48
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Keywords
- myostatin, Duchenne muscular dystrophy, mdx mice, muscle atrophy, blocking antibodies, muscle mass, muscle strength, muscle degeneration, creatine kinase, TGF-beta superfamily, skeletal muscle growth
- MeSH terms
- Animals, Antibodies, Body Weight, Creatine Kinase, Male, Muscular Dystrophy, Animal, Organ Size, Transforming Growth Factor beta, Mice, Inbred mdx, Muscle, Skeletal, Muscle Fibers, Skeletal, Muscular Dystrophy, Duchenne, Mice, Myostatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.